突变型急性髓系白血病是否进行移植 - Suppr

Suppr

超能文献

Transplant or no transplant for mutated AML.

作者信息

Badar Talha, Shahzad Moazzam, Atallah Ehab, Litzow Mark R, Kharfan-Dabaja Mohamed A

出版信息

Oncotarget. 2024 Oct 1;15:674-676. doi: 10.18632/oncotarget.28652.

DOI:10.18632/oncotarget.28652

PMID:39352794

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11444334/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7955/11444334/6a57f21eb704/oncotarget-15-28652-g001.jpg

相似文献

Transplant or no transplant for mutated AML.突变型急性髓系白血病是否进行移植

Oncotarget. 2024 Oct 1;15:674-676. doi: 10.18632/oncotarget.28652.

Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.伴有 17 号染色体异常的急性髓系白血病或骨髓增生异常综合征，以及造血干细胞移植与否的长期预后。

Leuk Res. 2020 Aug;95:106402. doi: 10.1016/j.leukres.2020.106402. Epub 2020 Jun 18.

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.TP53 突变型急性髓系白血病采用不断发展的一线治疗方案的结果：异基因干细胞移植对生存的影响。

Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.

Current status and new treatment approaches in TP53 mutated AML.TP53 基因突变型 AML 的现状和新的治疗方法。

Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11.

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.TP53 基因突变与骨髓增生异常综合征和急性髓系白血病患者感染增加和造血细胞移植率降低相关。

Transplant Cell Ther. 2023 Jun;29(6):390.e1-390.e10. doi: 10.1016/j.jtct.2023.03.008. Epub 2023 Mar 9.

Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.TP53 突变的急性髓系白血病非西班牙裔黑人患者接受疾病导向治疗、异基因造血干细胞移植的差异。

Cancer. 2023 Mar 15;129(6):934-945. doi: 10.1002/cncr.34604. Epub 2022 Dec 21.

[Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].[TP53异常的骨髓增生异常综合征/急性髓系白血病患者接受异基因造血干细胞移植的生存疗效]

Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):222-229. doi: 10.3760/cma.j.issn.0253-2727.2023.03.008.

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with mutations.影响伴有突变的急性髓系白血病/骨髓增生异常综合征患者异基因移植后生存的预后因素。

Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.其他细胞遗传学特征决定了 TP53 突变急性髓系白血病患者的移植预后。

Cancer. 2022 Aug 1;128(15):2922-2931. doi: 10.1002/cncr.34268. Epub 2022 May 25.

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.接受异基因造血干细胞移植治疗的高危急性髓系白血病患者的TP53突变

Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. Epub 2016 Jan 13.

本文引用的文献

Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.急性髓系白血病患者中“多打击”与“单打击”TP53改变的预后影响：来自髓系恶性肿瘤和肿瘤疾病联盟的研究结果。

Haematologica. 2024 Nov 1;109(11):3533-3542. doi: 10.3324/haematol.2024.285000.

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.复发或反应不佳的急性髓系白血病患者的缓解诱导与立即进行异基因造血干细胞移植（ASAP）：一项随机、开放标签、3期、非劣效性试验。

Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4.

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。

Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).接受首次诱导或挽救治疗后接受异基因干细胞移植的TP53突变急性髓系白血病患者的生存情况：髓系恶性肿瘤与肿瘤性疾病联盟（COMMAND）的结果

Leukemia. 2023 Apr;37(4):799-806. doi: 10.1038/s41375-023-01847-7. Epub 2023 Feb 18.

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.移植前诱导和巩固周期对 AML 异基因移植结局的影响：CIBMTR 在 3113 例 AML 患者中的分析。

Leukemia. 2023 May;37(5):1006-1017. doi: 10.1038/s41375-022-01738-3. Epub 2022 Oct 30.

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.TP53 突变型骨髓增生异常综合征和急性髓系白血病：生物学、当前治疗和未来方向。

Cancer Discov. 2022 Nov 2;12(11):2516-2529. doi: 10.1158/2159-8290.CD-22-0332.

Cancer. 2022 Aug 1;128(15):2922-2931. doi: 10.1002/cncr.34268. Epub 2022 May 25.

Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.突变型 TP53 急性髓系白血病和高危骨髓增生异常综合征的分子特征。

Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472.

Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验